Clinical Trial

Potential Role of Sirtuins As Epigenetic Biomarkers of the Patient with Atherosclerosis or Calcific Aortic Stenosis

Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated March 11, 2025 (before its estimated October 2025 completion). Its status may not reflect the trial's current state.
Summary
The project aims to shed light on the role of Sirtuins, enzymes belonging to the third class of histone deacetylases (class III) involved in epigenetic modifications (deacetylation), focusing mainly on Sirtuin 6 (SIRT6), as a regulator of atherosclerosis and severe aortic valve stenosis through molecular-based and epigenetic studies in human VSMC cells.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2024-03-22; most recent amendment 2025-03-07.
Trial Details
NCT Number NCT06337227
Lead Sponsor IRCCS SYNLAB SDN
Collaborators: Federico II University
Conditions Atherosclerosis and Calcific Aortic Stenosis with and Without Diabetes
Enrollment 3 participants
Start Date 2023-10-19
Primary Completion 2025-10 (estimated)
Study Completion 2026-10 (estimated)
Updated on ClinicalTrials.gov 2025-03-11